A menu of glaucoma treatments includes options to fit all scenarios
Physician presents pearls for effective use, leading to positive outcomes for patients.
Physician presents pearls for effective use, leading to positive outcomes for patients.
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.
The A-IOL aims to correct both near and distance eyesight, reduce reliance on glasses or contact lenses, have no glare or halos, and restore the…
The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of…
The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.
David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company’s path toward developing treatment for neurotrophic…
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
The A-IOL aims to correct both near and distance eyesight, reduce reliance on glasses or contact lenses, have no glare or halos, and restore the…
Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and…
More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.